Huiying Medical Technology Raises Hundreds of Millions of Yuan in Series C2

The medical imaging artificial intelligence company Huiying Medical Technology Co., Ltd. (hereinafter referred to as "HY") announced that it has successfully completed the latest round (C2 round) of hundreds of millions of yuan in financing, setting a record for the company's financing. CEC Capital continues to act as the exclusive financial advisor in this transaction. 

This round of financing was co-invested by Shougang Fund, a fund of Sinopharm Group, and Kunjian Xintai, and old shareholders such as CDH Investment, Delta Capital, and Bluerun Ventures continued to increase.

Huiying Medical Technology Co., Ltd. is a state-level high-tech enterprise focusing on artificial intelligence for medical imaging, with headquarter in Beijing and branch in silicon valley.

With the technology of computer vision and deep learning, HY is taking the lead in medical imaging industry. HY has cooperated with more than 800 top hospitals domestically on the scopes of clinic application and scientific research, including China PLA General Hospital, Peking Union Medical College Hospital, Beijing Friendship Hospital, Cancer Hospital Chinese Academy of Medical Science, Beijing Cancer Hospital, The Third Affiliated Hospital of Zhengzhou University, Ordos Health Alliance etc. HY provides a complete set of medical diagnosis and data analysis solutions based on artificial intelligence, cloud computing and big data, and is committed to create the intelligent, digital and mobile medical images. HY is the only high-tech and innovation company in domestic market can cover the whole process from diagnosis and treatment to scientific research. 

HY has established the AI collaboration lab with Stanford University, Tsinghua Strait Research Institute, Intel and Beijing Friendship Hospital. HY also established strategic cooperation relationships with big giants closely, e.g. China Telecom, China Unicom, Tencent, Alibaba, Sino pharm etc. Through the collaboration, HY is abounded with top talents globally, which making efforts on becoming a respectable world-class AI unicorn company.

Up to now, the company has awarded nearly 30 industry honors such as 2017 Future Medical Top 100, 2017 Global Best AI Startup Company, 2018 China Unicorn Top 100, Forbes 2018 China Top 50 Most Innovative List and graduated from the first phase of Tencent AI Accelerator.